臨床外科79巻7号

2024年07月発行

特集 外科医が知っておくべき 肝胆膵腫瘍に対する薬物療法 胆道・膵臓

膵癌に対する術前補助療法

著者： 伊東剛¹ 渋谷和人¹ 木村七菜¹ 深澤美奈¹ 楠弘充¹ 山本皓太郎¹ 村主遼¹ 白井祥睦¹ 吉岡伊作¹ 藤井努¹

所属機関： ¹富山大学学術研究部医学系消化器・腫瘍・総合外科

ページ範囲：P.768 - P.773

【ポイント】
◆膵癌は外科的切除が可能であったとしても術後早期の再発が多く，化学療法や放射線療法を行う集学的治療が重要である．
◆本邦では，切除可能膵癌に対する術前補助療法としてゲムシタビンおよびS-1併用療法が標準治療と位置づけられている．
◆切除可能境界以上の進行膵癌に対する術前補助療法は化学放射線療法や化学療法が推奨されているが，コンセンサスの得られたレジメンはいまだないのが現状である．

参考文献

1）がん情報サービス：がんの統計2022．〔https://ganjoho.jp/public/qa_links/report/statistics/2022_jp.html〕

2）Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al：Preoperative/neoadjuvant therapy in pancreatic cancer：a systematic review and meta-analysis of response and resection percentages. PLoS Med 7：e1000267, 2010

3）NCCN Guidelines. Pancreatic adenocarcinoma, version 1. 2024〔https://www.nccn.org/guidelines/category_1〕

4）Oettle H, Post S, Neuhaus P, et al：Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer：a randomized controlled trial. JAMA 297：267-277, 2007

5）Oettle H, Post S, Neuhaus P, et al：Adjuvant chemotherapy with gemcitabine and long-term outcomes among Patients with resected pancreatic cancer：the CONKO-001 randomized trial. JAMA 310：1473-1481, 2013

6）Uesaka K, Boku N, Fukutomi A, et al：Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer：aphase 3, Open-label randomized, non-inferiority trial（JASPAC01）. Lancet 388：248-257, 2016

7）Conroy T, Hammel P, Hebbar M, et al：FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379：2395-2406, 2018

8）Neoptolemos JP, Palmer DH, Ghaneh P, et al：Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer（ESPAC-4）：a multicentre, open-label, randomised, phase 3 trial. Lancet 389：1011-1024, 2017

9）海野倫明：膵癌に対する術前化学療法．日消誌120：639-642, 2023

10）Motoi F, Kosuge T, Ueno H, et al：Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer（PREP-02/JSAP05）. Jpn J Clin Oncol 49：190-194, 2019

11）Versteijne E, Suker M, Groothuis K, et al：Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer：results of the Dutch randomized phase Ⅲ PREOPANC trial. J Clin Oncol 38：1763-1773, 2020

12）Mokdad AA, Minter RM, Zhu H, et al：Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer：a propensity score matched analysis. J Clin Oncol 35：515-522, 2017

13）Katz MH, Shi Q, Ahmad SA, et al：Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer：alliance for clinical trials in oncology trial A021101. JAMA Surg 151：e161137, 2016

14）Nagakawa Y, Hosokawa Y, Nakayama H, et al：A phase Ⅱ trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline resectable pancreatic cancer with arterial involvement. Cancer Chemother Pharmacol 79：951-957, 2017

15）Murphy JE, Wo JY, Ryan DP, et al：Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma：a phase 2 clinical trial. JAMA Oncol 4：963-969, 2018

16）Hayashi T, Nakamura T, Kimura Y, et al：Phase 2 study of neoadjuvant treatment of sequential S-1-based concurrent chemoradiation therapy followed by systemic chemotherapy with gemcitabine for borderline resectable pancreatic adenocarcinoma（HOPS-BR 01）. Int J Radiat Oncol Biol Phys 105：606-617, 2019

17）Tran NH, Sahai V, Griffith KA, et al：Phase 2 trial of neoadjuvant FOLFIRINOX and intensity modulated radiation therapy concurrent with fixed-dose rate-gemcitabine in patients with borderline resectable pancreatic cancer. Int J Radiat Oncol Biol Phys 106：124-133, 2020

18）Masui T, Nagai K, Anazawa T, et al：Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment；a prospective, open-label, phase Ⅱ study in a single institution. BMC Cancer 22：119, 2022

19）Takahashi S, Ohno I, Ikeda M, et al：Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer：a phase Ⅱ open-label multicenter prospective trial（JASPAC05）. Ann Surg 276：e510-e517, 2022

20）Jang JY, Han Y, Lee H, et al：Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer：a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg 268：215-222, 2018

21）Takahashi S, Ohno I, Ikeda M, et al：Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer：a phase Ⅱ open-label multicenter prospective trial（JASPAC05）. Ann Surg 276：e510-e517, 2022

22）Tsuchida H, Fujii T, Mizuma M, et al：Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy：A nationwide, cancer registry-based study from the Japan Pancreas Society. Surgery 166：997-1003, 2019

23）Aoki S, Mizuma M, Hayashi H, et al：Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Pancreatology 20：1711-1717, 2020

24）Igarashi T, Fukasawa M, Watanabe T, et al：Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal washing cytology. Ann Gastroenterol Surg 8：124-132, 2023

25）Fukasawa M, Watanabe T, Tanaka H, et al：Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytology. J Hepatobiliary Pancreat Sci 30：1261-1272, 2023

26）Ariake K, Mizuma M, Motoi F, et al：Preceding systemic chemotherapy for patients with pancreatic ductal adenocarcinoma with positive peritoneal cytology provides survival benefit compared with up-front surgery. Ann Surg Oncol 28：6246-6254, 2021